0001209191-13-046858.txt : 20131002 0001209191-13-046858.hdr.sgml : 20131002 20131002201504 ACCESSION NUMBER: 0001209191-13-046858 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131002 DATE AS OF CHANGE: 20131002 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ophthotech Corp. CENTRAL INDEX KEY: 0001410939 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 VAUGHN DRIVE STREET 2: SUITE 106 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-945-6050 MAIL ADDRESS: STREET 1: 5 VAUGHN DRIVE STREET 2: SUITE 106 CITY: PRINCETON STATE: NJ ZIP: 08540 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Novo A/S CENTRAL INDEX KEY: 0001388325 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36080 FILM NUMBER: 131131907 BUSINESS ADDRESS: STREET 1: KROGSHOJVEJ 41 CITY: BAGSVAERD STATE: G7 ZIP: DK-2880 BUSINESS PHONE: 45 8824 8824 MAIL ADDRESS: STREET 1: KROGSHOJVEJ 41 CITY: BAGSVAERD STATE: G7 ZIP: DK-2880 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2013-09-30 0 0001410939 Ophthotech Corp. OPHT 0001388325 Novo A/S TUBORG HAVNEVEJ 19 HELLERUP G7 2900 DENMARK 0 0 1 1 SEE REMARKS COMMON STOCK 2013-09-30 4 C 0 6441819 0.00 A 6441819 D COMMON STOCK 2013-09-30 4 P 0 455000 22.00 A 6896819 D SERIES A PREFERRED STOCK 2013-09-30 4 C 0 14374443 0.00 D COMMON STOCK 2806937 0 D SERIES B PREFERRED STOCK 2013-09-30 4 C 0 5208334 0.00 D COMMON STOCK 995520 0 D SERIES C PREFERRED STOCK 2013-09-30 4 C 0 15438009 0.00 D COMMON STOCK 2639359 0 D Series A, B and C Preferred Stock (collectively, the "Preferred Stock") has no expiration date and was converted upon the closing of the Issuer's initial public offering (the "IPO Closing") on a one-for-5.9000 basis, as adjusted to give effect to the reverse stock split of the Issuer's Common Stock at the IPO Closing. Includes three (3) shares received as a result of the aggregation of fractional shares at the time of conversion and stock split. Includes 370,591 shares of Common Stock issuable upon conversion as dividends that accrued on each series of Preferred Stock prior to conversion. Includes 112,752 shares of Common Stock issuable upon conversion as dividends that accrued on each series of Preferred Stock prior to conversion. Includes 22,748 shares of Common Stock issuable upon conversion as dividends that accrued on each series of Preferred Stock prior to conversion. Novo A/S is a Danish limited liability company. The board of directors of Novo A/S (the "Novo Board"), currently comprised of Sten Scheibye, Goran Ando, Jorgen Boe, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares. /S/ Thorkil Kastberg Christensen, Chief Financial Officer of Novo A/S 2013-09-30